Abstract | Background: Methods: All patients with thoracic esophageal squamous-cell carcinoma (T2N+M0-T3-4N0/+M0) (according to the eighth edition of the National Comprehensive Cancer Network guidelines) who underwent immune neoadjuvant immunochemotherapy with programmed cell death protein 1 (PD-1) combined with paclitaxel plus cisplatin or nedaplatin in the Affiliated Cancer Hospital of Zhengzhou University, China, between November 2019 and August 2021 were included in this study. All patients underwent surgical resection. We developed a response [ tumor regression grade (TRG)] prediction model using the least absolute shrinkage and selection operator (LASSO) regression incorporating factors associated with response. The accuracy of the prediction model was then validated. Results: We included 79 patients who underwent neoadjuvant immunotherapy combined with chemotherapy, aged 48-78 years (62.05±6.67), including 21 males and 58 females. There were five cases of immune-related pneumonia, of which three cases were diagnosed as immune-related pneumonia during the perioperative period, and one case of immune-related thyroid dysfunction changes. After LASSO regression, the factors that were independently associated with TRG were clinical T stage before neoadjuvant therapy, clinical N stage before neoadjuvant therapy, albumin level difference from before to after neoadjuvant therapy, white blood cell (WBC) count before neoadjuvant therapy, and T stage before surgery. We constructed a prediction model, plotted the nomogram, and verified its accuracy. Its Brier score was 0.13, its calibration slope was 0.98, and its C-index was 0.90 (95% CI: 0.82-0.97). Conclusions:
|
Authors | Yongkui Yu, Wei Wang, Zimin Qin, Haomiao Li, Qi Liu, Haibo Ma, Haibo Sun, Thomas L Bauer, Jose M Pimiento, Emmanuel Gabriel, Thomas Birdas, Yin Li, Wenqun Xing |
Journal | Annals of translational medicine
(Ann Transl Med)
Vol. 10
Issue 2
Pg. 102
(Jan 2022)
ISSN: 2305-5839 [Print] China |
PMID | 35282099
(Publication Type: Journal Article)
|
Copyright | 2022 Annals of Translational Medicine. All rights reserved. |